Thursday, March 28, 2019
In today days atrial Fibrillation (AF) is the more or less common cardiac dysrhythmia that is often seen in clinical practice. There atomic number 18 700,000 slams in the USA each year and 15% of it caused by atrial Fibrillation. For a long period of time warfarin was the only literal anticoagulant uncommitted in the US for patients with atrial fibrillation to prevent stroke events. Recently a pertly oral anticoagulants, including apixaban, dabigatran, and rivaroxaban have been developed and became available in the US for the stoke prevention and systemic embolism for patients with atrial fibrillation. Now, when all three new anticoagulants are available as an alternative to warfarin for the same recital, they make the health care providers question which performer is the scoop out and for which patients. New agents have practical advantages over warfarin that has some(prenominal) limitations such as need for monitoring, regular dose adjustment, food and do drugs interact ion and side effects. The major goal of the health care providers is to ordain the safest and the most effective alternative drug and dose to each one-on-one patient with AF. However, the approval for clinical use by the Food and dose Administration (FDA) and the European Medicine Agency differ for anticoagulants and their dosages, and for the individual indication (Harenberg & Kraemer, 2012). Thus, more research needs to be done regarding the monitoring tools for new anticoagulant agents, and gallop the use of these agents to other patient population.Keywords anticoagulants, apixaban, dabigatran, rivaroxaban, warfarin, atrial fibrillation, stroke.warfarin or New Anticoagulant for Stroke Prevention in Patients with Atrial FibrillationAtrial Fibrillation (AF) is one of the most common arrhythmias that ... ...s and may not richly understand the importance of their medication, therefor, Advanced Practical Nurse should take all(prenominal) opportunity to reinforce the need of the patients to adhere to anticoagulant therapy and may hightail it an important role in patients adherence by providing constant education about their health condition and the importance of their medication. more research should be done on new oral anticoagulants with unalike study population and similar patients that are seen in everyday clinical practice as well as attempt to define the best pharmacodynamic monitoring tools. Research should be conducted to outline monitoring protocol including time relative to dosing and frequency as well as therapeutic targets. employ these strategies, future trials could enhance further the efficacy and safety of these new agents and could extend their use to new indications.